Clinical trials

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Status: Recruiting

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Participants needed: 200

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Jun 23, 2026Locations: 34

Eligibility criteria

Participant has a primary diagnosis of recurrent MDD (moderate or severe) or per... [+4]

A current or prior psychiatric disorder diagnosis in the last 1 year that was th... [+2]

Status: Recruiting

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Participants needed: 100

Trial details

Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Jun 23, 2026Locations: 18

Eligibility criteria

Medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipola... [+2]

Comorbid parkinsonism (drug-induced or otherwise) or more than a minimal level o... [+5]

Status: Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Participants needed: 850

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Jun 22, 2026Locations: 98

Eligibility criteria

Participant has a primary diagnosis of recurrent MDD (moderate or severe) or per... [+3]

A current or prior psychiatric disorder diagnosis in the last 1 year that was th... [+1]

Status: Recruiting

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Participants needed: 50

Trial details

Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Jun 16, 2026Locations: 22

Eligibility criteria

18 years of age or older [+2]

Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prom... [+2]

Status: Recruiting

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

Participants needed: 560

Trial details

Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Jun 5, 2026Locations: 20

Eligibility criteria

Participant has a primary diagnosis of schizophrenia established by a comprehens... [+2]

Participant has an unstable or poorly controlled medical condition or chronic di... [+4]

Status: Recruiting

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

Participants needed: 600

Trial details

Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Jun 5, 2026Locations: 57

Eligibility criteria

Participant has a primary diagnosis of schizophrenia [+2]

Participant has known hypersensitivity to any component of the formulation of NB... [+5]

Status: Recruiting

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

Participants needed: 120

Trial details

Phase: Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: May 26, 2026Locations: 5

Eligibility criteria

18 to 55 years of age [+3]

Considered to be at imminent risk of suicide or injury to self or others. [+4]

Status: Recruiting

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Participants needed: 284

Trial details

Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: May 15, 2026Locations: 15

Eligibility criteria

Participant has a primary diagnosis of schizophrenia [+3]

Participant has known hypersensitivity to any component of the formulation of NB... [+5]

Status: Not yet recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.

Participants needed: 20

Trial details

Phase: Phase 2Age: 3-47Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Apr 17, 2026

Eligibility criteria

Have a medically confirmed diagnosis of classic CAH (salt wasting or simple viri... [+3]

Have a known or suspected diagnosis of any of the other forms of classic CAH. [+2]

Status: Recruiting

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.

Participants needed: 150

Trial details

Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Mar 24, 2026Locations: 6

Eligibility criteria

Participant has a primary diagnosis of bipolar I disorder. [+2]

Any unstable or poorly controlled medical condition or chronic disease (includin... [+3]

Status: Recruiting

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

Participants needed: 550

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Mar 19, 2026Locations: 45

Eligibility criteria

Participant has a primary diagnosis of recurrent MDD (moderate or severe) or per... [+4]

A current or prior psychiatric disorder diagnosis in the last 1 year that was th... [+2]

Status: Recruiting

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Participants needed: 284

Trial details

Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Mar 6, 2026Locations: 21

Eligibility criteria

Participant has a primary diagnosis of schizophrenia [+3]

Participant has known hypersensitivity to any component of the formulation of NB... [+5]

Status: Recruiting

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Participants needed: 200

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Dec 1, 2025Locations: 10

Eligibility criteria

Participant has a primary diagnosis of recurrent MDD (moderate or severe) or per... [+4]

A current or prior psychiatric disorder diagnosis in the last 1 year that was th... [+2]

Status: Recruiting

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Participants needed: 200

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Neurocrine BiosciencesUpdated: Oct 29, 2025Locations: 18

Eligibility criteria

Participant has a primary diagnosis of recurrent MDD (moderate or severe) or per... [+4]

A current or prior psychiatric disorder diagnosis in the last 1 year that was th... [+2]